contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


carlsquare-research-update-biosergen-promising-interim-data-as-bsg005-saves-lives

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Biosergen är verksamt inom bioteknik. Bolaget är specialiserat inom forskning och utveckling av diverse läkemedel. Produktportföljen inkluderar exempelvis bolagets produkt BSG005, ett svampdödande läkemedel i klinisk fas. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten bedrivs i Norge. Biosergen grundades år 2004 och har sitt huvudkontor i Solna.

Biosergen

Carlsquare Equity Research has updated its view on Biosergen following updates from the ongoing study and the report for the third quarter.Read the full update here.About CarlsquareCarlsquare...

<div class="mfn-body"><p>Carlsquare Equity Research has updated its view on Biosergen following updates from the ongoing study and the report for the third quarter.</p><p><a rel="noopener" href="https://carlsquare.com/research-update-biosergen-promising-interim-data-as-bsg005-saves-lives/">Read the full update here.</a></p></div><div class="mfn-footer mfn-about mfn-ff317aff455d"><p><strong class="mfn-heading-1">About Carlsquare</strong></p><hr><p>Carlsquare is a global research firm and financial advisor, focusing on M&amp;A, Equity<br>Research and Growth Equity. Carlsquare has 150 employees with deep sector knowledge in all 11<br>GICS sectors. The senior equity research team has extensive experience about the stock<br>environment and several business sectors. The team produces company research reports,<br>independent valuations and trading notes. The group have offices in Canada, Denmark, France, Germany, Poland, Sweden, United Kingdom and United States. <a rel="noopener" href="https://www.carlsquare.com/">Read more</a></p></div><div class="mfn-footer mfn-contacts mfn-6ca94a02479e"><p><strong class="mfn-heading-1">Contacts</strong></p><hr><p><strong>MARKUS AUGUSTSSON</strong><br>Head of Equity Research<br><a rel="noopener" href="mailto:markus.augustsson@carlsquare.com">markus.augustsson@carlsquare.com</a><br>+46 (0)76 235 03 20<br>&nbsp;<br><strong>NIKLAS ELMHAMMER</strong><br>Senior Equity Analyst<br>niklas.elmhammer@carlsquare.com<br>+46 (0)70 898 39 59</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/1932d5a3-0b31-44fd-a218-ac5af9cd53a8/research-update-biosergen-promising-interim-data-as-bsg005-saves-lives.pdf" class="mfn-generated mfn-primary">Research update Biosergen: Promising interim data as BSG005 saves lives</a></p></div>

Carlsquare: Research update Biosergen: Promising interim data as BSG005 saves lives

Return on capital (ROE, ROI, ROIC, RONIC)

What does negative working capital mean and why is it a good thing?

Drug development investment: Value creation through M&As and licensing agreements

Income statement

Amazon and Costco in Sweden: A looming threat that Nordic retailers ignore at their peril

Beställ vårt nyhetsbrev — inget användarkonto krävs!